In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.

Autor: Bakthavatchalam YD; Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India., Routray A; Medical Affairs, Pfizer Limited, Mumbai, Maharashtra, India. Electronic address: Abhisek.Routray@pfizer.com., Mane A; Medical Affairs, Pfizer Limited, Mumbai, Maharashtra, India., Kamat S; Medical Affairs, Pfizer Limited, Mumbai, Maharashtra, India., Gupta A; Fortis Escorts Heart Institute, New Delhi, New Delhi, India., Bari AK; Department of Pathology & Microbiology, Breach Candy Hospital Trust, Mumbai, Maharashtra, India., Rohit A; Department of Microbiology and Infection Control, Madras Medical Mission, NITTE University, Chennai, Tamil Nadu, India., Poojary A; Department of Pathology & Microbiology, Breach Candy Hospital Trust, Mumbai, Maharashtra, India., Mukherjee DN; Department of Clinical Microbiology & Infectious Diseases, Woodlands Multispecialty Hospital, Kolkata, West Bengal, India., Sethuraman N; Department of Microbiology, Apollo hospitals, Chennai, Tamil Nadu,  India., Munshi N; Grand Medical Foundation, Ruby Hall Hospital, Department of Laboratory Pune, Pune, Maharashtra, India., Shah S; Department of Microbiology, Kokilaben Dhirubhai Ambani Hospital and Research Institute, Rao Saheb Achutrao, Mumbai, Maharashtra, India., Balaji V; Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India., Gupta Y; Department of Microbiology, Fortis Escort Hospital, Jaipur, Rajasthan, India.
Jazyk: angličtina
Zdroj: Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2022 May; Vol. 103 (1), pp. 115652. Date of Electronic Publication: 2022 Jan 31.
DOI: 10.1016/j.diagmicrobio.2022.115652
Abstrakt: ATLAS (Antimicrobial Testing Leadership and Surveillance) detects trends in multi-drug resistance longitudinally over time. In the present study, the in vitro activity of ceftazidime-avibactam and comparators was analyzed against Escherichia coli (n = 458) and Klebsiella pneumoniae (n = 455)  isolates obtained from 9 centers across India. The overall susceptibility to ceftazidime-avibactam was observed to be 72% among K. pneumoniae isolates and 87% among E. coli isolates. Among the tested carbapenem resistant isolates, 51% of CR-K. pneumoniae and 24% of CR-E. coli were susceptible to ceftazidime- avibactam. OXA-48 like was identified in 52% of the K. pneumoniae isolates followed by co-production of NDM with OXA-48 like in 27%. NDM was predominantly identified in 68% of the E. coli isolates followed by OXA-48 like in 24% isolates. The findings suggest that ceftazidime- avibactam is a reasonable alternative to standard therapy for management of carbapenem resistant Enterobacterales infections particularly with K. pneumoniae and E. coli with the OXA-48 like genotype.
(Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: